6533b824fe1ef96bd12808ee
RESEARCH PRODUCT
Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).
Ana LluchTadeusz PienkowskiLuca GianniJuan De La Haba-rodriguezLing-ming TsengYoung-hyuck ImVichien SrimuninnimitBrigitte PoirierGiulia BianchiElżbieta StarosławskaJose Luiz PedriniGraham RossSeock-ah ImPaolo MorandiV. McnallyVladimir SemiglazovPinuccia ValagussaMei-ching LiuHannah Douthwaitesubject
OncologyCancer Researchmedicine.medical_specialtybusiness.industryAdjuvant chemotherapyLocally advancedOncologyDocetaxelTrastuzumabInternal medicineMedicinePertuzumabbusinessmedicine.drugdescription
505 Background: InNeoSphere, four cycles of T+D, P+T+D, P+T, or P+D, followed by surgery and adjuvant chemotherapy plus conventional T, were evaluated in 417 women with locally advanced, inflammato...
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-05-20 | Journal of Clinical Oncology |